AP NEWS

Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2018 - ResearchAndMarkets.com

December 21, 2018

DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The  “Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2018”  drug pipelines has been added to  ResearchAndMarkets.com’s  offering.

Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Peroxisome Proliferator-Activated Receptor (PPAR) Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Peroxisome Proliferator-Activated Receptor (PPAR) Agonist Pipeline Products in Clinical Stages

6. Peroxisome Proliferator-Activated Receptor (PPAR) Agonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies MentionedEsperion TherapeuticsStrekiDARA BioSciencesT3D TherapeuticsLigand PharmaceuticalsMinoryx TherapeuticsBiophytisGenfitsanofi-aventisOmeros Corporation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/97dvp3/peroxisome?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005270/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/21/2018 09:24 AM/DISC: 12/21/2018 09:24 AM

http://www.businesswire.com/news/home/20181221005270/en

AP RADIO
Update hourly